Abbott Laboratories (ABT)vsInMode Ltd (INMD)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
INMD
InMode Ltd
$13.75
+0.36%
HEALTHCARE · Cap: $857.24M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 11865% more annual revenue ($44.33B vs $370.50M). INMD leads profitability with a 25.3% profit margin vs 14.7%. ABT appears more attractively valued with a PEG of 1.52. INMD earns a higher WallStSmart Score of 58/100 (C).
ABT
Buy51
out of 100
Grade: C-
INMD
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Margin of Safety
-46.5%
Fair Value
$9.72
Current Price
$13.75
$4.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 25.0%
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Earnings declined 63.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : INMD
The strongest argument for INMD centers on P/E Ratio, Price/Book, Debt/Equity. Profitability is solid with margins at 25.3% and operating margin at 25.0%.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : INMD
The primary concerns for INMD are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ABT profiles as a value stock while INMD is a mature play — different risk/reward profiles.
INMD carries more volatility with a beta of 2.19 — expect wider price swings.
INMD is growing revenue faster at 6.1% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Bottom Line
INMD scores higher overall (58/100 vs 51/100), backed by strong 25.3% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →InMode Ltd
HEALTHCARE · MEDICAL DEVICES · USA
InMode Ltd. designs, develops, manufactures and markets minimally invasive aesthetic medical products based on its proprietary RF-assisted lipolysis and deep subdermal fractional RF technologies. The company is headquartered in Yokneam, Israel.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?